Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing's Disease - Yahoo Finance

PUTEAUX, France, March 29, 2022--Recordati Rare Diseases announce today the publication of positive results from the Phase III LINC 4 study of Isturisa in...

The LINC 4 study demonstrated superiority of Isturisa® (osilodrostat) over placebo in achieving cortisol normalisation during the 12-week, double-blind, randomised phase (77% vs 8%, P<0.0001). Is… [+10403 chars]

full article...